The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Artificial intelligence analysis of CCNG1 expression in tumors: A novel biomarker in development for anti-CCNG1 targeted therapy.
 
Erlinda Maria Gordon
Stock and Other Ownership Interests - Counterpoint Biomedica; Delta Next-Gene
Speakers' Bureau - AADi
Research Funding - Bristol Mers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of patents on targeting pharmaceutical agents to injured tissues
 
Nadezhda Omelchenko
No Relationships to Disclose
 
Caroline Eid
No Relationships to Disclose
 
Samantha Jeffrey
No Relationships to Disclose
 
Zhanna Shekhovtsova
Employment - BostonGene
 
Kushal Suryamohan
Employment - BostonGene
 
Elan Younesi
No Relationships to Disclose
 
Amir Ahari
No Relationships to Disclose
 
Neal Shiv Chawla
No Relationships to Disclose
 
Don Arlen Brigham
No Relationships to Disclose
 
Michael Morse
Honoraria - AstraZeneca/Daiichi Sankyo; Bayer; Boehringer Ingelheim; Eisai; Exelixis; Genentech/Roche; Ipsen; Lexicon; Merck; Novartis; QED Therapeutics; Sanofi; SERVIER; Taiho Pharmaceutical; Tersera
Speakers' Bureau - AstraZeneca; Eisai; Exelixis; Genentech/Roche; Ipsen; SERVIER; Taiho Pharmaceutical
Research Funding - Advanced Accelerator Applications (Inst); AlphaVax (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lexicon (Inst); MedImmune (Inst); Merck (Inst); Onyx (Inst); Precision Biologics (Inst)
Patents, Royalties, Other Intellectual Property - Compositions And Methods For Modulating And Redirecting Immune Responses Publication number: 20170015758 Inventors: Scott A. HAMMOND, Michael A. MORSE, Takuya OSADA, Herbert Kim LYERLY; PHARMACEUTICAL PRODUCT, MEDICAL FOOD OR DIETARY SUPPLEMENT FOR PREVENTING CANCER AND INFLAMMATORY DISEASES Publication number: 20170246136 Applicant: OliVentures, Inc. Inventors: Carlos María Peña Díaz, Guillermo Muñoz Fernández, Michael Morse; Vaccines against antigens involved in therapy resistance and methods of using same Patent number: 9956276 Assignee Duke University
 
Sant P. Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma